Anish Patel Sells 48,300 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel sold 48,300 shares of the firm’s stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $27.99, for a total value of $1,351,917.00. Following the completion of the sale, the chief operating officer directly owned 215,011 shares of the company’s stock, valued at $6,018,157.89. This trade represents a 18.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Anish Patel also recently made the following trade(s):

• On Monday, December 8th, Anish Patel sold 6,663 shares of Enliven Therapeutics stock. The stock was sold at an average price of $21.02, for a total value of $140,056.26.
• On Friday, November 7th, Anish Patel sold 6,667 shares of Enliven Therapeutics stock. The stock was sold at an average price of $17.40, for a total value of $116,005.80.

Enliven Therapeutics Trading Up 1.2%

Shares of ELVN stock opened at $26.05 on Thursday. The firm has a fifty day simple moving average of $19.46 and a two-hundred day simple moving average of $20.05. Enliven Therapeutics, Inc. has a 12 month low of $13.30 and a 12 month high of $29.98. The firm has a market capitalization of $1.55 billion, a PE ratio of -14.16 and a beta of 0.41.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.11. On average, equities analysts predict that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ELVN has been the subject of several analyst reports. Wall Street Zen raised Enliven Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $41.00.

Hedge Funds Weigh In On Enliven Therapeutics

Several hedge funds have recently modified their holdings of ELVN. Goldman Sachs Group Inc. grew its stake in Enliven Therapeutics by 61.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 211,752 shares of the company’s stock valued at $4,167,000 after purchasing an additional 80,506 shares during the period. Affinity Asset Advisors LLC purchased a new position in shares of Enliven Therapeutics in the 2nd quarter worth about $8,024,000. Geode Capital Management LLC grew its position in Enliven Therapeutics by 7.8% during the second quarter. Geode Capital Management LLC now owns 882,753 shares of the company’s stock valued at $17,711,000 after buying an additional 63,580 shares during the period. Franklin Resources Inc. increased its holdings in Enliven Therapeutics by 2,029.3% during the second quarter. Franklin Resources Inc. now owns 430,240 shares of the company’s stock worth $8,631,000 after buying an additional 410,034 shares during the last quarter. Finally, KLP Kapitalforvaltning AS raised its position in Enliven Therapeutics by 58.1% in the second quarter. KLP Kapitalforvaltning AS now owns 6,800 shares of the company’s stock worth $136,000 after acquiring an additional 2,500 shares during the period. Institutional investors own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.